AMENDMENT NO. 1 TO AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology • May 10th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the “Amendment No. 1”), effective as of October 22, 2015 (the “Amendment No. 1 Effective Date”), is entered into by and between Fred Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (“FHCRC”), and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (“LICENSEE”).
FIRST AMENDMENT TO PATENT AND TECHNOLOGYPatent and Technology • March 31st, 2017 • Q BioMed Inc. • Pharmaceutical preparations
THIS AGREEMENT (the “Amended Agreement”), dated September 6, 2016, amends the Patent and Technology License and Purchase Option Agreement (the “License Agreement”) entered into on May 30, 2016 by and between (i) Q BioMed Inc. (“Q Bio”) and (ii) Bio-Nucleonics Inc. (“BNI”) (together, the “Parties”)
AMENDMENT NO. 1 TO AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology • May 10th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the “Amendment No. 1”), effective as of October 22, 2015 (the “Amendment No. 1 Effective Date”), is entered into by and between Fred Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (“FHCRC”), and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (“LICENSEE”).
EXCLUSIVE, WORLD WIDE PATENT AND TECHNOLOGY LICENSE AND ASSIGNMENT AGREEMENTPatent and Technology • May 6th, 2003 • Ai Software Inc • Services-prepackaged software
THIS EXCLUSIVE LICENSE AND ASSIGNMENT AGREEMENT (the "Agreement") is made and entered into on May 1st, 2003, between A.I. Software Inc., a company incorporated under the laws of the state of Nevada, having its address at 1030 West Georgia Street, Suite 1208, Vancouver, BC, Canada, V6E 2Y3 (the "Licensee"), and Technion Research and Development Foundation Ltd., having a place of business at Technion City, Haifa 32000, Israel (the "Technion"), Yeda Research and Development Company Ltd., having its address at P.O. Box 95, Rehovot 76100, Israel ("Yeda"), Dr. Shoshana Merchav, having a residence at 9 Farrer Drive, #03-04 Sommerville Grandeur, Singapore 259279 ("Merchav"), Shai Meretzki, having a residence at Raul Wallenberg 38, Haifa, Israel ("Meretzki"), Alex Korat, having a residence at Shlomsky 27, Haifa, Israel ("Korat"), and Amir Uziel, having a residence at HaKormim 9, Rishon LeZion, Israel ("Uziel") (Merchav and Meretzki shall collectively be referred to as the "Inventors") (Meretzki
FIRST AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AND PURCHASE OPTION AGREEMENTPatent and Technology • October 17th, 2016 • Q BioMed Inc. • Pharmaceutical preparations
THIS AGREEMENT (the “Amended Agreement”), dated September __, 2015, amends the Patent and Technology License and Purchase Option Agreement (the “License Agreement”) entered into on May 30, 2016 by and between (i) Q BioMed Inc. (“Q Bio”) and (ii) Bio-Nucleonics Inc. (“BNI”) (together, the “Parties”)
